Bluebird bio, Inc. (NASDAQ: BLUE) shares are trading lower in Monday's after-hours session after the company announced a proposed public offering of $150 million
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to provide top-line results from a Phase 2 clinical trial of
Due to the recent achievements of GLP-1s, Goldman Sachs sees significant potential for Eli Lilly And Co (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), and other companies to venture
Cara Therapeutics Inc (NASDAQ: CARA) announced the outcome from the dose-finding Part A of the KIND 1 study evaluating the efficacy and safety of oral difelikefalin as adjunct therapy to topical corticosteroids (TCS) for moderate-to-severe pruritus in adult patients with
Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion protein currently in a Phase 3 study in IgA Nephropathy (IgAN).
Set-up of first BioNTainer as high-tech manufacturing solution for mRNA medicines is a critical step in establishing a resilient vaccine ecosystem in Africa and future pandemic preparednessBioNTech plans to complete all
Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing:
Stork Provides Continuous Monitoring of Oxygen Saturation, Pulse Rate, and Skin Temperature, with Alarms, for Sick and Healthy Babies at HomeMasimo (NASDAQ:MASI), a global leader in innovative monitoring technologies